About Us

Eureka Therapeutics is a preclinical-stage company developing innovative T cell immunotherapies for the treatment of solid tumors. Our first clinical program for the treatment of liver cancer is projected to enter the clinic in 2017.
549-GIRL-WINTER-5596

Recent News

Renowned physician-scientist, David A. Scheinberg, MD, PhD, to join Scientific Advisory Board of Eureka Therapeutics

Our Science and Technology

Faster, safer immunotherapies that defeat cancer cells while muting cytokine storm
Biotechnology

Pipeline

Our pipeline encompasses T cell therapies targeting well-studied cancer specific antigens, e.g. testis antigens, mutated oncogenes, viral antigens. Our lead program for liver cancer, ET1402, is expected to enter Phase I in 2017.
View of Pacific Coast Highway  at Garrapata State Park  California. 1

Partnerships

Collaborations are a vital pillar of our strategy for developing first-in-class immunotherapy for solid tumors. We believe that collaboration is key to achieving a “cure for cancer.” We welcome partnership opportunities around our technology platforms and product pipeline.

Upcoming Events

  1. ASCO 2017 Annual Meeting

    June 2 @ 8:00 am - June 6 @ 5:00 pm
  2. Bay Area Biotech Forum

    June 8 @ 7:30 am - 10:00 am
Hiring Now!
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.